CADL vs. COLL, AKBA, SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, and PRAX
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs. Its Competitors
Candel Therapeutics (NASDAQ:CADL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Candel Therapeutics had 10 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 14 mentions for Candel Therapeutics and 4 mentions for Collegium Pharmaceutical. Candel Therapeutics' average media sentiment score of 0.76 beat Collegium Pharmaceutical's score of 0.60 indicating that Candel Therapeutics is being referred to more favorably in the media.
Candel Therapeutics presently has a consensus price target of $22.00, indicating a potential upside of 331.37%. Collegium Pharmaceutical has a consensus price target of $43.75, indicating a potential upside of 44.06%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Candel Therapeutics is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Candel Therapeutics has a beta of -0.91, indicating that its share price is 191% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
13.9% of Candel Therapeutics shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Collegium Pharmaceutical has a net margin of 6.61% compared to Candel Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 99.08% beat Candel Therapeutics' return on equity.
Summary
Candel Therapeutics and Collegium Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 7/3/2025 by MarketBeat.com Staff
Free CADL Stock Alerts